| Followers | 141 |
| Posts | 5785 |
| Boards Moderated | 0 |
| Alias Born | 06/09/2020 |
Thursday, December 07, 2023 7:42:52 AM
If you were not paid for an opinion that incentivize you to ignore facts, it would actually be possible for you to be wiser instead of just ranting of the lies from your transcript.
You very often take Al Musellas words out of context, when you would like to manipulate us into believing, that he would choose Optune, if he was in need of a glioblastoma treatment. Everytime you just "cut of" the context, so that it supports your paid for fictional narrative.
Al Musella wrote this about Matthew Williams (Novocure affiliated) bullshit regarding the DCVax-L trial:
He also refuted the bullshit from these two (Novocure affiliated) doctors.
You could also read the JAMA Oncology journal of course peer reviewed by 73 peers, but that would go against the whole point about your financial incentive for being here at all of course.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
And then the authors response:
You very often take Al Musellas words out of context, when you would like to manipulate us into believing, that he would choose Optune, if he was in need of a glioblastoma treatment. Everytime you just "cut of" the context, so that it supports your paid for fictional narrative.
Al Musella wrote this about Matthew Williams (Novocure affiliated) bullshit regarding the DCVax-L trial:
He also refuted the bullshit from these two (Novocure affiliated) doctors.
You could also read the JAMA Oncology journal of course peer reviewed by 73 peers, but that would go against the whole point about your financial incentive for being here at all of course.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
And then the authors response:
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM

